Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01526681 · ClinicalTrials.gov registry record

Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction

A clinical trial of Peripheral Nerve Injuries, sponsored by Axogen Corporation.

Active
Registry status
3,126
Enrollment target
20
Study locations

NCT01526681: Active study of Peripheral Nerve Injuries, sponsored by Axogen Corporation.

NCT01526681 is a study of Peripheral Nerve Injuries that is active but no longer recruiting, run by Axogen Corporation. The registered enrollment target is 3,126 participants, above the 71-participant average among 8 other Peripheral Nerve Injuries trials with a reported enrollment target (4303% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01526681, a study of Peripheral Nerve Injuries, is active but no longer recruiting, sponsored by Axogen Corporation.

ACTIVE NOT RECRUITING
Registry status
3,126 participants
Enrollment target
20
Study locations

Study Summary

This study is a registry of general use of Avance Nerve Graft and is intended to evaluate the uses, response rates, and safety of Avance Nerve Graft in the real-life clinical setting. Optional addendums 1 and 2 included in the protocol are intended to establish comparative groups and focused subgroups within the registry.

Primary Outcome

Participants will be followed through the course of their recovery based on Physician's standard of care practice or until lost to follow-up.

Conditions Studied

Interventions

  • OTHER Processed Human Nerve Graft
  • OTHER Standard Treatment, Autogenous Nerve Graft, Direct Suture, etc.
  • OTHER Autogenous Nerve Graft
  • DEVICE Nerve Tube Conduit
  • PROCEDURE Autologous Breast Reconstruction with Neurotization

Study Locations (20)

California

  • RANGER & MATCH: University of California - Irvine - Orange
  • RANGER & MATCH: The Buncke Clinic - San Francisco
  • Sensation-NOW: Stanford University - Stanford

Maryland

  • RANGER: Johns Hopkins University - Baltimore
  • Sensation-NOW: Johns Hopkins University - Baltimore
  • RANGER: Walter Reed National Military Medical Center - Bethesda

Arizona

  • RANGER & MATCH: Arizona Center for Hand Surgery - Phoenix
  • RANGER: Phoenix Children's Hospital - Phoenix

Florida

  • RANGER: University of Miami - Miami
  • RANGER & MATCH: Florida Orthopaedic Institute - Tampa

Kansas

  • RANGER & MATCH: University of Kansas Medical Center - Kansas City
  • Sensation-NOW: University of Kansas Medical Center - Kansas City

Colorado

  • Sensation-NOW: University of Colorado School of Medicine - Aurora

District of Columbia

  • Sensation-NOW: George Washington University - Washington D.C.

Georgia

  • RANGER: Hand & Upper Extremity Center of Georgia/Children's Hospital of Atlanta - Atlanta

Trial Details

FieldValue
Enrollment Target 3,126 participants
Start Date 2008-11
Est. Completion 2028-11
Axogen Corporation

10 total trials

What the registry record for NCT01526681 still lists

NCT01526681 is an observational study that tracks outcomes without assigning an intervention. Its 3,126 participants enrollment target places it among the larger protocols in the corpus, above the 71-participant average among 8 other Peripheral Nerve Injuries trials with a reported enrollment target (4303% higher).

The record links to 1 condition, with Peripheral Nerve Injuries appearing as the primary indexed condition, and to 5 interventions - of which Processed Human Nerve Graft is the first listed.

NCT01526681 names 20 study sites across 13 states, led by California, Maryland, Arizona.

Frequently Asked Questions

What is clinical trial NCT01526681 about?

NCT01526681 is a clinical study titled "Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction". This study is a registry of general use of Avance Nerve Graft and is intended to evaluate the uses, response rates, and safety of Avance Nerve Graft in the real-life clinical setting. Optional addendums 1 and 2 included in the protocol are intended to establish comparative groups and focused subgrou...

What is the current status of trial NCT01526681?

This trial is currently active not recruiting. The enrollment target is 3,126 participants. The study started on 2008-11. Estimated completion is 2028-11.

What conditions does trial NCT01526681 study?

This clinical trial studies the following conditions: Peripheral Nerve Injuries.

What interventions are being tested in trial NCT01526681?

The interventions under investigation include: Processed Human Nerve Graft (OTHER), Standard Treatment, Autogenous Nerve Graft, Direct Suture, etc. (OTHER), Autogenous Nerve Graft (OTHER), Nerve Tube Conduit (DEVICE), Autologous Breast Reconstruction with Neurotization (PROCEDURE).

Who is sponsoring clinical trial NCT01526681?

This trial is sponsored by Axogen Corporation, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01526681 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Peripheral Nerve Injuries

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01526681's enrollment target sits among peer trials

3,126 1st of 8 higher than 8 of 8 other Peripheral Nerve Injuries trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Peripheral Nerve Injuries trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05051722 · 3,110 participants

    Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

  • NCT06224205 · 3,150 participants · NA

    Digital Detection of Dementia (D Cubed) Studies: D3

  • NCT04722822 · 3,100 participants · NA

    The HPV 9-10 Trial: Early Initiation of HPV Vaccination

  • NCT05534243 · 3,090 participants · NA

    The ED-AWARENESS-2 Trial

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01526681, the US trial registry maintained by the National Library of Medicine. NCT01526681 (large enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.